GenesisCare, the largest private provider of radiotherapy services in Australia and the UK, held a very successful contouring and planning event; enabling more clinical oncologists to deliver or refer patients for Stereotactic Ablative Body Radiotherapy (SABR).
Clinical oncologists (covering a variation of body sites) from across Portsmouth, Southampton and Windsor took the opportunity to be part of this highly interactive, educational and networking event.
The event was hosted by renowned SABR expert, Dr Veni Ezhil who was able to demonstrate what this pathway can offer to patients with limited volume tumours but for whom surgery may not be an optimal treatment. Stereotactic Ablative Radiotherapy (SABR), also known as Stereotactic Body Radiation Therapy (SBRT), is highly focused radiation treatment that gives an intense dose of radiation concentrated on a tumour, while limiting the dose to the surrounding organs.
At the event, leading SABR expert, Dr Ezhil focussed on lung and peripheral lung tumours; and spine and bone metastases. Each delegate was able to contour the body using sophisticated computer software, to fully understand how a patient would be treated and the outcomes.
GenesisCare SABR treatment centres
GenesisCare has now completed SABR treatment for seven patients at Guildford, Nottingham, Maidstone and Southampton centres and has another five referrals in progress. By the end of the year, all ten GenesisCare centres will be SABR enabled and new technologies such as Surface Guided Radiotherapy (SGRT) are also being introduced to work alongside, ensuring the highest standards of patient care.
Clinical Oncologist, Dr Catherine Heath from Southampton said: “I found the SABR contouring day a very useful introduction to SABR for various different sites and it shed light on a few things that I was unsure of.
“I also enjoyed contouring on the 4DCT so I now know what the lung team are up to!”
Further SABR contouring events are planned to give oncologists the knowledge, experience and confidence required to consider this treatment for their patients.
For more information, comments, interviews or images please contact firstname.lastname@example.org.